Evaluation of Clinical Outcomes in COVID-19 Patients Receiving Remdesivir in Outpatient Setting Outcomes in COVID-19 patients receiving outpatient Remdesivir
Iranian Journal of Pharmaceutical Sciences,
دوره 20 شماره 1 (2024),
8 May 2024
,
صفحه 69-79
https://doi.org/10.22037/ijps.v20i1.42191
چکیده
Remdesivir (RDV) is one of the drugs that showed beneficial effects in treating Coronavirus disease in 2019 (COVID-19). We performed the present study to evaluate the safety of Remdesivir administration in the outpatient setting. In this study, 512 patients with COVID-19 participated. When selected patients came to the hospital for the drug injection on the appointed day, the vital signs and the percentage of oxygen saturation were measured before Remdesivir administration. During and after the injection, if any drug side effects occurred, it was recorded. Laboratory tests, including Complete blood count differential, C-reactive protein, Liver function tests, Blood urea nitrogen, and creatinine, were checked before and between the treatment courses. The mean age of participants was 46.19±14.20 years, and 46.9% were men. 97.4 percent of patients did not experience any side effects following Remdesivir administration. The amounts of laboratory components like White blood cells, Platelet, Alanine aminotransferase, and Blood urea nitrogen were significantly increased. In contrast, Hemoglobin, C-reactive protein, Aspartate aminotransferase, Alkaline phosphatase, and Creatinine levels were significantly decreased following the administration of Remdesivir compared to baseline values.
- Remdesivir
- RDV
- Adverse effects
- Side effects
- Outcome
- Outpatient
- COVID-19
ارجاع به مقاله
مراجع
worldometers. COVID-19 CORONAVIRUS PANDEMIC 2022 [cited 2024 January 15]. Available from: https://www.worldometers.info/coronavirus/.
who. Coronavirus disease (COVID-19 ) 2022. https://www.who.int/health-topics/coronavirus#.
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet] (2022).
Health NIo. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020. Available form: https://www covid19treatmentguidelines nih gov/,(Accessed on 16 September, 2021) (2021).
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19 [cited 2022 April 25]. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2022/4/veklury-remdesivir-is-first-and-only-approved-treatment-for-pediatric-patients-under-12-years-of-age-with-covid19.
Srivastava K, Singh MK. Drug repurposing in COVID-19: a review with past, present and future. Metabolism Open (2021) 12:100121.
Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, Holten AR, et al. Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: A randomized trial. Annals of internal medicine (2021) 174(9):1261-9.
Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, Van Doremalen N, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature (2020) 585(7824):273-6.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, et al. Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine (2020) 382(24):2327-36.
Angamo MT, Mohammed MA, Peterson GM. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection (2021):1-15.
Mohamad Rahimi M, Jahantabi E, Lotfi B, Forouzesh M, Valizadeh R, Farshid S. Renal and liver injury following the treatment of COVID-19 by remdesivir. Journal of Nephropathology (2021) 10(2):1-4.
Kuno T, Miyamoto Y, Iwagami M, Ishimaru M, Takahashi M, Egorova NN. The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids. Journal of Antimicrobial Chemotherapy (2021) 76(10):2690-6.
Lamb YN. Remdesivir: first approval. Drugs (2020) 80:1355-63.
Pasquini Z, Montalti R, Temperoni C, Canovari B, Mancini M, Tempesta M, Pimpini D, et al. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. Journal of Antimicrobial Chemotherapy (2020) 75(11):3359-65.
Gupta V, Ingawale S, Bhondve A, Khot W, Salagre S, Sonawale A, Joshi K, et al. Clinical Study of Use of Remdesivir and Tocilizumab in Severely Ill COVID-19 Patients. The Journal of the Association of Physicians of India (2021) 69(7):14-9.
Diaz GA, Christensen AB, Pusch T, Goulet D, Chang S-C, Grunkemeier GL, McKelvey PA, et al. Remdesivir and Mortality in Patients with COVID-19. Clin infect dis (2021).
Wong CK, Lau KT, Au IC, Xiong X, Chung MS, Lau EH, Cowling BJ. Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America (2021).
Olender SA, Walunas TL, Martinez E, Perez KK, Castagna A, Wang S, Kurbegov D, et al., editors. Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. Open forum infectious diseases; 2021: Oxford University Press US.
Consortium WST. Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. New England journal of medicine (2021) 384(6):497-511.
Russo A, Binetti E, Borrazzo C, Cacciola EG, Battistini L, Ceccarelli G, Mastroianni CM, et al. Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: a prospective clinical experience. Journal of clinical medicine (2021) 10(17):3784.
Ohl ME, Miller DR, Lund BC, Kobayashi T, Miell KR, Beck BF, Alexander B, et al. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19. JAMA network open (2021) 4(7):e2114741-e.
Almaghlouth NK, Anyiam FE, Shah S, Haq S, Attia MJ, Guevara R, Antony S. The Use of Single Therapy With Tocilizumab Versus Combination Therapy With Remdesivir and Tocilizumab in SARS-CoV-2 Patients in El Paso, Texas. Cureus (2021) 13(7).
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, et al. Remdesivir for the treatment of Covid-19—preliminary report. New England Journal of Medicine (2020) 383(19):1813-36.
Joo E-J, Ko J-H, Kim SE, Kang S-J, Baek JH, Heo EY, Shi HJ, et al. Clinical and virologic effectiveness of remdesivir treatment for severe coronavirus disease 2019 (COVID-19) in Korea: a nationwide multicenter retrospective cohort study. Journal of Korean medical science (2021) 36(11).
Spinner CD, Gottlieb RL, Criner GJ, López JRA, Cattelan AM, Viladomiu AS, Ogbuagu O, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. Jama (2020) 324(11):1048-57.
Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, Gubertini G, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacological research (2020) 158:104899.
Lee C, Ahn MY, Byeon K, Choi J-P, Hahm C, Kim H, Kim S, et al. Clinical experience with use of remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2: a case series. Infection & chemotherapy (2020) 52(3):369.
Dubert M, Visseaux B, Isernia V, Bouadma L, Deconinck L, Patrier J, Wicky P-H, et al. Case report study of the first five COVID-19 patients treated with remdesivir in France. International journal of infectious diseases (2020) 98:290-3.
McCoy JA, Short WR, Srinivas SK, Levine LD, Hirshberg A. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. American journal of obstetrics & gynecology MFM (2020) 2(3):100164.
Montastruc F, Thuriot S, Durrieu G. Hepatic disorders with the use of remdesivir for coronavirus 2019. Clinical Gastroenterology and Hepatology (2020) 18(12):2835-6.
Flisiak R, Zarębska-Michaluk D, Berkan-Kawińska A, Tudrujek-Zdunek M, Rogalska M, Piekarska A, Kozielewicz D, et al. Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study. medRxiv (2020).
Mahajan L, AP Singh G. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. Indian Journal of Anaesthesia (2021) 65(Suppl 1):S41.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. New England Journal of Medicine (2022) 386(4):305-15.
Blair HA. Remdesivir: a review in COVID-19. Drugs (2023) 83(13):1215-37.
- چکیده مشاهده شده: 22 بار
- IJPS_Volume20_Issue1_Pages69-79 (English) دانلود شده: 6 بار